Neurofibromatosis Type 2
Also known as: Neurofibromatosis 2 / Neurofibromatosis, type 2 (acoustic neurofibromatosis) / Neurofibromatosis Type II / NF2 / Neurofibromatosis, type 2 / Neurofibromatosis, type 2 (disorder) / Neurofibromatosis, unspecified / Neurofibromatoses / Neurofibromatosis / Neurofibromatosis (morphologic abnormality) / Neurofibromatosis syndrome (disorder)
Drug | Drug Name | Drug Description |
---|
Drug | Drug Name | Target | Type |
---|
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB12707 | AR-42 | 0 | Terminated | 1 |
DB01590 | Everolimus | 0 | Completed | 1 |
DB01259 | Lapatinib | 0 | Completed | 1 |
DB00112 | Bevacizumab | 1 | Active Not Recruiting | 1 |
DB00002 | Cetuximab | 1 | Active Not Recruiting | 1 |
DB14123 | Menthol | 1 | Active Not Recruiting | 1 |
DB00877 | Sirolimus | 1 | Active Not Recruiting | 1 |
DB06287 | Temsirolimus | 1 | Active Not Recruiting | 1 |
DB00313 | Valproic acid | 1 | Active Not Recruiting | 1 |
DB00254 | Doxycycline | 1 / 2 | Recruiting | 1 |
DB00945 | Acetylsalicylic acid | 2 | Recruiting | 1 |
DB06626 | Axitinib | 2 | Completed | 1 |
DB00112 | Bevacizumab | 2 | Completed | 3 |
DB12267 | Brigatinib | 2 | Recruiting | 1 |
DB08865 | Crizotinib | 2 | Active Not Recruiting | 1 |
DB06423 | Endostatin | 2 | Completed | 1 |
DB01590 | Everolimus | 2 | Completed | 2 |
DB01590 | Everolimus | 2 | Terminated | 1 |
DB11737 | Icotinib | 2 | Completed | 1 |
DB01259 | Lapatinib | 2 | Completed | 1 |
DB11828 | Neratinib | 2 | Recruiting | 1 |
DB05173 | PTC299 | 2 | Terminated | 1 |
DB11689 | Selumetinib | 2 | Active Not Recruiting | 1 |
DB11925 | Vistusertib | 2 | Completed | 1 |
DB12707 | AR-42 | 2 / 3 | Recruiting | 1 |
DB00112 | Bevacizumab | Not Available | Recruiting | 1 |
DB14907 | Bevacizumab zirconium Zr-89 | Not Available | Recruiting | 1 |